Skip to main content
letter
. 2015 Apr 17;5(4):e308. doi: 10.1038/bcj.2015.33

Figure 1.

Figure 1

(a) Probabilities of OS based on day 28 response in patients with steroid-refractory aGVHD after anti-CD25 mAb therapy. (b) Cumulative incidence of NRM based on day 28 response in patients with steroid-refractory aGVHD after anti-CD25 mAb therapy.